Iradimed Co (IRMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.09B
Last updated: Nov 17, 2026 at 11:05 AM ET
Iradimed Co (IRMD) Stock Forecast
Analysts expect Iradimed (IRMD) to earn $2.10 per share in the fiscal year ending Dec 31, 2026, on revenue of $92.20M. Of 3 analysts, 2 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.33, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 2 | 66.7% |
| Hold | 1 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 16.2% and revenue estimates rise 11.0%.
- Fiscal year ending Dec 31, 2026
- $2.10
- EPS consensus, revenue $92.20M
- Fiscal year ending Dec 31, 2027
- $2.44
- EPS consensus, revenue $102.33M
- Next report
- Feb 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.10 | $2.09 to $2.11 | 3 | $92.20M | $91.70M to $92.70M | 3 |
| Dec 31, 2027 | $2.44 | $2.41 to $2.47 | 3 | $102.33M | $102.10M to $102.80M | 3 |
Quarterly Estimates
The EPS consensus falls from $0.61 for the quarter ending Dec 31, 2026 to $0.58 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.61 | $0.58 to $0.64 | 5 | $25.87M | $24.50M to $27.41M | 5 |
| Mar 31, 2027 | $0.58 | $0.56 to $0.61 | 3 | $24.95M | $24.10M to $25.80M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.5% from $2.09.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.10 | $2.11 | $2.11 | $2.09 | $2.09 | +0.3% |
| Fiscal year ending Dec 31, 2027 | $2.44 | $2.45 | $2.45 | $2.41 | $2.41 | +1.1% |
| Quarter ending Mar 31, 2027 | $0.58 | $0.60 | $0.60 | $0.59 | $0.59 | -1.7% |
Frequently Asked Questions About IRMD
What is the IRMD stock forecast?
Consensus analyst estimates put Iradimed's EPS at $2.10 for the fiscal year ending Dec 31, 2026, on revenue of $92.20M. The consensus rating from 3 analysts is Buy.
How do analysts rate IRMD stock?
Of 3 analysts covering Iradimed, 0 rate it Strong Buy, 2 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IRMD next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.10, with estimates from $2.09 to $2.11 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.44, with estimates from $2.41 to $2.47 from 3 analysts.
What revenue do analysts expect from Iradimed next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $92.20M, with estimates from $91.70M to $92.70M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $102.33M, with estimates from $102.10M to $102.80M.
How many analysts cover IRMD?
3 analysts rate Iradimed stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IRMD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts